Mannkind (MNKD) Cash & Current Investments (2010 - 2026)
Mannkind's (MNKD) quarterly Cash & Current Investments came in at $134.6 million in Q1 2026, down 26.15% year-on-year from $182.3 million in Q1 2025, and down 21.78% on a QoQ basis from $172.1 million in Q4 2025.
Mannkind (MNKD) Cash & Current Investments (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has 17 years of Cash & Current Investments data on file, last reported at $134.6 million in Q1 2026.
- On a quarterly basis, Cash & Current Investments fell 26.15% year-over-year to $134.6 million in Q1 2026; TTM through Mar 2026 was $134.6 million, a 26.15% decrease from a year earlier, with the FY2025 full-year figure at $172.1 million, down 13.08% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $134.6 million, down from $172.1 million in the prior quarter.
- Over the last five years, Cash & Current Investments for MNKD reached as high as $300.7 million in Q1 2024 and fell as low as $134.6 million in Q1 2026.
- Historically, Cash & Current Investments has averaged $195.8 million across 5 years, with a median of $172.1 million in 2025.
- Across the five-year window, Cash & Current Investments slumped 41.33% in 2022 and jumped 81.01% in 2024, its largest moves.
- Year by year, Cash & Current Investments stood at $170.8 million in 2022, then jumped by 72.73% to $295.1 million in 2023, then plunged by 32.91% to $198.0 million in 2024, then retreated by 13.08% to $172.1 million in 2025, then decreased by 21.78% to $134.6 million in 2026.
- Per Business Quant data, the three most recent Cash & Current Investments figures were $134.6 million in Q1 2026, $172.1 million in Q4 2025, and $260.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,094.26 Bn | 68,093.97 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,939.09 Bn | 1,939.02 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 123.34 Bn | 116.09 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.38 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.96 Bn | 62.96 Bn | - | - |
| 8 | Argenx Se | 56.38 Bn | 51.20 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Mannkind | 1.28 Bn | 1.15 Bn | 82.66 Mn | 134.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 134.61 Mn |
| Dec 31, 2025 | 172.09 Mn |
| Sep 30, 2025 | 260.78 Mn |
| Jun 30, 2025 | 179.73 Mn |
| Mar 31, 2025 | 182.28 Mn |
| Dec 31, 2024 | 197.99 Mn |
| Sep 30, 2024 | 252.32 Mn |
| Jun 30, 2024 | 248.49 Mn |
| Mar 31, 2024 | 300.73 Mn |
| Dec 31, 2023 | 295.10 Mn |
| Sep 30, 2023 | 141.02 Mn |
| Jun 30, 2023 | 144.35 Mn |
| Mar 31, 2023 | 166.14 Mn |
| Dec 31, 2022 | 170.85 Mn |
| Sep 30, 2022 | 165.04 Mn |
| Jun 30, 2022 | 154.16 Mn |
| Mar 31, 2022 | 162.40 Mn |
| Dec 31, 2021 | 204.12 Mn |
| Sep 30, 2021 | 139.05 Mn |
| Jun 30, 2021 | 162.49 Mn |